宫颈癌是最常见的女性生殖系统恶性肿瘤之一。在世界范围内,每年新发宫颈浸润癌47万例,另有23万患者死于宫颈浸润癌。即使经过根治性手术治疗或放疗,仍有35%的宫颈癌患者复发,其中盆腔复发占60%以上。宫颈癌的盆腔复发治疗十分困难,治疗手段有限,预后极差,5年生存率仅为0%～30%,平均存活期为7个月,中位生存期仅为5～18个月。无论初次治疗的方法是手术还是常规放疗,均由于解剖变异、周围组织粘连及已有的并发症对再次治疗带来了一定的困难,并易造成更严重的并发症。近年的研究表 Cervical cancer is one of the most common female reproductive system malignancies. Around the world, 470,000 new cases of invasive cervical cancer each year, and another 230,000 patients died of cervical cancer. Even after radical surgery or radiotherapy, 35% of cervical cancer patients still relapse, of which pelvic recurrence accounted for more than 60%. Cervical cancer pelvic recurrence treatment is very difficult, treatment is limited, the prognosis is extremely poor, 5-year survival rate was only 0% to 30%, the average survival of 7 months, the median survival of only 5 to 18 months. Regardless of whether the primary treatment is conventional surgery or conventional radiotherapy, anatomical variation, adhesions around the organization and the existing complications of re-treatment has brought some difficulties, and easily lead to more serious complications. Recent years research table